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Abstract
Background: It is widely accepted that atherosclerosis and inflammation are intimately linked. Monocytes play a
key role in both of these processes and we hypothesized that activation of inflammatory pathways in monocytes
would lead to, among others, proatherogenic changes in the monocyte transcriptome. Such differentially
expressed genes in circulating monocytes would be strong candidates for further investigation in disease
association studies.
Methods: Endotoxin, lipopolysaccharide (LPS), or saline control was infused in healthy volunteers. Monocyte RNA
was isolated, processed and hybridized to Hver 2.1.1 spotted cDNA microarrays. Differential expression of key genes
was confirmed by RT-PCR and results were compared to in vitro data obtained by our group to identify candidate
genes.
Results: All subjects who received LPS experienced the anticipated clinical response indicating successful
stimulation. One hour after LPS infusion, 11 genes were identified as being differentially expressed; 1 down
regulated and 10 up regulated. Four hours after LPS infusion, 28 genes were identified as being differentially
expressed; 3 being down regulated and 25 up regulated. No genes were significantly differentially expressed
following saline infusion. Comparison with results obtained in in vitro experiments lead to the identification of 6
strong candidate genes (BATF, BID, C3aR1, IL1RN, SEC61B and SLC43A3)
Conclusion: In vivo endotoxin exposure of healthy individuals resulted in the identification of several candidate
genes through which systemic inflammation links to atherosclerosis.
Keywords: Human, Monocytes, LPS infusion, Transcriptome, In Vivo
Background
Inflammation and atherosclerosis are closely linked. In
patients with chronic inflammation due to disorders
such as rheumatoid arthritis or systemic lupus erythe-
matodus (SLE), the incidence of cardiovascular disease
(CVD) is 2 to 50-fold higher [1,2]. Even after correction
for traditional risk factors, patients with chronic inflam-
matory disorders have accelerated plaque progression
[3]. Circulating levels of hsCRP (high sensitive C-Reac-
tive Protein), a biomarker for inflammation, are proven
to be a strong, independent predictor of future myocar-
dial infarction and stroke even among apparently
healthy asymptomatic men [4]. Finally, in a cohort of
healthy individuals, subjects with endotoxin levels
beyond 50 pg/ml (90th percentile) exhibited a threefold
increased risk of cardiovascular events (OR [95% CI],
2.9 [1.4-6.3]; p < 0.01) [5].
In vivo, monocytes bridge inflammation and athero-
sclerosis. They express TLR4, the receptor for endotoxin
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We hypothesized that endotoxin exposure in vivo
results in changes in monocyte transcriptome that could
lead to a more atherogenic phenotype. This would be
reflected by differential expression of, among others,
atherosclerosis related genes. We aimed to identify these




Endotoxin infusion in healthy volunteers
In order to mimic in vivo systemic inflammation asso-
ciated with endotoxemia, we used a model in which
healthy volunteers are exposed to lipopolysaccharide
(LPS), the endotoxin derived from gram negative bac-
teria [7]. Informed consent was obtained from healthy
Caucasian male volunteers for the study, which was
approved by the Institutional Review Board of the Aca-
demic Medical Center Amsterdam. Inclusion criteria
included: no history of sepsis or CVD; not having pre-
viously received endotoxin intravenously; non-smokers,
no use of any medication and free from any febrile ill-
ness in the month preceding the study. In all subjects, a
medical history, physical examination, routine laboratory
examination, electrocardiogram and chest X-ray were
performed. All experiments were performed after an
overnight fast.
A bolus of Escherichia coli endotoxin (LPS; catalog
number 1235503, lot G2B274; Pharmacopeial Conven-
tion, Inc, Rockville, USA; 1 ng/kg) was infused intrave-
nously in healthy volunteers. For controls, an equal
amount of endotoxin-free 0.9% NaCl (saline) was
infused. Vital signs, including temperature of the study
subjects, were monitored at the Intensive Care Unit by a
medical doctor who was present throughout the experi-
ments. The incidence, time and severity of clinical
symptoms associated with endotoxemia, were recorded.
Blood was regularly sampled for clinical chemistry and
hematological parameters. IL-6 levels were determined
using the Cytometric Bead Array technique (R&D sys-
tems, Minneapolis, MN, USA). Whole blood samples in
4% trisodium citrate were obtained at baseline (T = 0),
one hour (T = 1) and four hours (T = 4) after LPS
infusion.
Monocyte mRNA preparation
Whole blood was centrifuged 12 minutes at 300 g and
plasma was replaced with an equal volume of PBS buffer
containing 1.25% BSA and 2 mM EDTA (PBS/BSA/
EDTA). The samples were then layered onto 0.5 volume
Histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA)
and centrifuged at 400 g for 20 minutes. Mononuclear
cells were removed and washed twice with PBS/BSA/
EDTA buffer. An aliquot of 1 million peripheral mono-
nuclear blood cells were removed for flow cytometric
analysis. The remaining cells were used for monocyte
isolation using magnetic CD14+ microbeads (Miltenyi
Biotech GMBH, Bergisch Gladbach, Germany) according
to the manufacturer’s instructions. Briefly, 20 μl
microbeads and 80 μl PBS/BSA/EDTA containing 106
cells were mixed and incubated on ice for 15 minutes.
Cells were washed with PBS/BSA/EDTA before being
run on an MS column on a varioMACS (Miltenyi Bio-
tech, Cologne, GMBH). Cell purity was assessed on an
aliquot of cells by flow cytometry using anti-CD14
(CLB-mon/1, 8G3, Mouse IgG2a, Sanquin Reagents,
Amsterdam, The Netherlands). The purified cells were
then lysed in RNA Bee (TelTest Inc., Friendswood,
Texas, USA) and RNA extracted according to manufac-
turer’s protocol. The concentration of purified RNA was
quantified using a NanoDrop spectrophotometer (Nano-
Drop Technologies, Wilmington, Delaware, USA) and
quality assessed using an Agilent 2100 Bioanalyzer (Agi-
lent, Palo Alto, CA, USA). RNA purity was assessed by
Real-Time PCR (RT-PCR) using Taqman transcripts
specific for B-cells (CD19/Hs00174333_m1), T-cells
(CD3/Hs00167894_m1), erythroid cells (CD235a/
Hs00266777_m1), platelets (CD41/HS00166246_m1),
neutrophils (CD66a/Hs00174351_m1), monocytes
(CD14/Hs00169122_g1) and GAPDH (Hs99999905_m1)
as control. A total of 12 ng of RNA was reverse tran-
scribed and amplified using Taqman Transcription
Reagents according to the manufacturer’s protocol
(Applied Biosystems, Foster City, CA, USA). Assays
were run on an Mx4000 Multiplex Quantitative PCR
System (Stratagene Inc, La Jolla, California, USA). Only
those samples with a FACS purity > 80% were processed
to ensure reliability of results.
Monocyte cDNA preparation
Template Switching Polymerase Chain Reaction (TS-
PCR) was used to prepare amplified double stranded
(ds) copy DNA (cDNA) following manufacturer’s
instructions (BD Biosciences Clontech, Palo Alto, CA,
USA). Amplifications were performed with either 10 ng
(23 cycles) or 100 ng (17 cycles) of starting material, as
described previously [8]. Amplified cDNA was subse-
quently purified using the QIAquick PCR Purification
Kit (QIAGEN Inc., Chatsworth, UK) according to manu-
facturer’s protocol with two amendments. Firstly, sam-
ples were washed three times in 0.7 mL PE buffer.
Secondly, for elution, 50 μL of sterile water was added,
the column was left to stand for 2 minutes and then
centrifuged. Purified cDNA was quantified using a
NanoDrop and fragment length assessed on 1.0% agar-
ose gel. Performance of the amplification was assessed
using RT-PCR as above.
Microarray processing
Out of the 11 LPS infusion experiments the 5 samples
with the highest purity based on FACS and RT-PCR
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and sufficient yield were chosen for arraying at T = 0 vs.
T = 1 and T = 0 vs. T = 4. Similarly, 4 out of the 5 were
chosen for the control experiments for the T = 0 vs. T =
1 and 2 of the 5 samples for the T = 0 vs. T = 1. A total
of 250 ng of amplified cDNA was labelled by incorpora-
tion of Cy3 or Cy5 dCTP using the Bioprime Labelling
Kit (Invitrogen Ltd, Paisley, UK). Labelled products were
purified on Autoseq G-50 columns (GE Healthcare,
Buckinghamshire, United Kingdom) before differential
labelling. Biologically paired pre- and post-infusion sam-
ples were pooled and hybridized to Hver 2.1.1 cDNA
micro-arrays (Wellcome Trust Sanger Institute; WTSI).
Hybridization and washing of the arrays were performed
according to WTSI protocols. Processed slides were
promptly scanned at 10- μm resolution on an Agilent
Micro-array Scanner (G2505B; Agilent Technologies,
Stockport, United Kingdom). Images were exported into
GenePix version 4.1 (Molecular Devices, Sunnyvale, CA,
USA) for spotfinding and feature extraction. In accor-
dance with MIAME (Minimum Information About a
Micro-array Experiments) regulations, all data were
deposited into ArrayExpress database at http://www.ebi.
ac.uk[9,10].
Data analysis
Data was analyzed using R-project version 2.2.0. Fea-
tures were included if all of the following criteria were
met: (i) Manually unflagged in Genepix 6.0 (Axon
Instruments, Foster City, CA, USA); (ii) (Δ median-
mean)/median intensity difference < 0.1;
(iii) Saturation < 20%; (iv) Mean/standard deviation
(SD) > 2; (v) Intensities of background (BG) + 1SD >
90% and G + 2 SD > 80%. In addition, the feature had
to be either up or down regulated in at least 50% of the
arrays, in order to pass the inclusion threshold. LPS and
control samples were analysed separately in a linear
mixed effects model with corrections for false discovery
rates (FDR) As cut-off we selected a FDR < 0.005, a pos-
terior probability of differential expression > 0.95. The
foldchanges had to be greater than two and present in
at least 70% of the arrays.
Microarray results validation
RT-PCR was used to confirm the observations from the
comparative microarray study in the 6 LPS samples not
used for Microarray for the following transcripts chosen
at random: SLA1 (Hs00153504_m1); BATF
(Hs00232390_m1); C3aR1 (Hs00377780_m1); AKIP
(Hs00610917_g1); ILRN (Hs00174099_m1); TIMP1
(Hs00171558_m1); VCAN (Hs00171642_m1).
RNA (100 ng) was reverse transcribed using the Taq-
Man RT kit (Applied Biosystems), from which 0.5 ng
cDNA was then used as template for RT-PCR following
the manufacturer’s instructions (Applied Biosystems).
Reactions were incubated at 50°C for 2 minutes then 95°
C for 10 minutes, and RT-PCR reactions were
performed over 40 cycles (95°C for 15 seconds, 60°C for
1 minute) on an MX-4000 (Stratagene, La Jolla, CA).
Threshold values (Ct) were normalized to GAPDH to
allow comparison between samples.
In Vivo and In Vitro Data Synthesis
Datamining in silico of the differentially expressed genes
was performed using public databases and tools includ-
ing biomart, iHOP, pubmed and reactome. Data from
the in vitro study was used to select genes which were
differentially expressed in both the in vivo and in vitro




Endotoxin infusion in healthy volunteers
In total, 16 healthy men with an average age of 23 ± 1
years (mean ± SD) meeting the inclusion criteria partici-
pated; 11 for LPS infusion and five as controls. Medical
history, physical examination, routine laboratory exami-
nation, electrocardiogram and chest X-ray were normal.
All subjects receiving LPS experienced a clinical
response consisting of nausea, malaise, chills, muscle
ache and fever. Plasma/Serum IL-6 increased signifi-
cantly (Figure 1). No such effects were observed in the
control group.
Monocyte cDNA preparation
The monocyte count differed significantly between LPS
and control experiments at the first hour (p < 0.05) (Fig-
ure 2). In the LPS infusion experiments, monocyte
count dropped 55% in the first hour followed by a slow
Figure 1 IL-6 values increase to a maximum value three hours
after LPS infusion. IL-6 levels were determined using the
Cytometric Bead Array technique (R&D systems, Minneapolis, MN,
USA).
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increase towards normal at four hours. In the control
experiments, monocyte count varied slightly but did not
decrease as observed after LPS infusion (Figure 2). Sum-
mary data for all samples and those included in the
study is shown in additional file 2 and 3; supplementary
table 1 and 2. RT-PCR performed pre- and post-amplifi-
cation demonstrated minimal contamination of selected
RNA samples by other cell types and non-biased ampli-
fication (Data not shown).
Microarray processing
For the T = 0 vs. T = 1 experiments, 10 arrays were
hybridised with LPS-stimulated samples and 8 with con-
trol samples. On average 19% of spots passed the strin-
gent quality control criteria. One hour after LPS
infusion (T = 1), 11 genes with a known function were
differentially expressed, of which, 1 was down regulated
and 10 unregulated (Table 1 and Figure 3) with fold-
changes ranging from 2.0 to 5.8.
For the T = 0 vs. T = 4 experiments, 10 arrays were
hybridised with LPS-stimulated samples and 4 arrays
with control samples. On average 26% of spots passed
the stringent quality control criteria. In total 28 genes
were identified as being differentially expressed in
monocytes following LPS stimulation, of which 3 were
down regulated and 25 up regulated (see Table 2 and
Figure 3). The fold changes ranged from 2.0 to 5.7.
Interestingly, AKIP was found to be differentially
expressed at both one and four hours after LPS
infusion.
Figure 2 Monocyte count is significantly lower in the LPS
infusion experiments compared to saline at T = 1.
Table 1 Genes differentially expressed one hour after LPS infusion
Ensembl ID HUGO geneID Full name foldchange p-value
ENSG00000172409 CLP1 Pre-mRNA cleavage complex II protein Clp1 0,47 0,001
ENSG00000197766 CDF Complement factor D precursor 2,02 0,003
ENSG00000175592 FOSL1 Fos-related antigen 1 2,05 0,001
ENSG00000175602 DIPA Delta-interacting protein A 2,05 0,001
ENSG00000166008 MAGEA9 Melanoma-associated antigen 9 2,37 0,001
ENSG00000136689 IL1RN Interleukin-1 receptor antagonist protein precursor 2,41 0,003
ENSG00000179271 PLINP-1 Papillomavirus L2-interacting nuclear protein 1 2,69 0,002
ENSG00000181667 PTPRCAP Protein tyrosine phosphatase receptor type C-associated protein 2,85 0,005
ENSG00000175756 AKIP Aurora kinase A-interacting protein 3,01 0,001
ENSG00000196783 CCL3L1 Small inducible cytokine A3-like 1 precursor 3,25 0,002
ENSG00000129277 CCL4 Small inducible cytokine A4 precursor 5,87 0,001
No genes were differentially expressed in the controls at T = 0 vs. T = 1.
Figure 3 Except for AKIP, microarray (MA) and RT-PCR fold
changes are comparable. AKIP-1; Differential expression of AKIP in
one hour post infusion samples. AKIP-4; Differential expression of
AKIP in four hours post infusion samples.
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We did not identify any genes that were significantly
differentially expressed in the control experiments at
either T = 1 or T = 4 confirming that the differential
expression observed, whilst limited, is associated with
LPS infusion.
Microarray data validation
Using quantitative RT-PCR, we were able to confirm the
differential expression of 7 of 8 genes tested (Figure 3).
Validation was performed on RNA from individuals who
had not been part of the subset analysed by microarray,
thus highlighting that the changes observed are univer-
sal. Absolute fold changes varied between the micro-
array and Taqman results, however in all cases, except
for AKIP (both at T = 1 and T = 4), the direction of dif-
ferential expression was conserved.
In Vitro Experiments
In the in vitro experiments a total 1127 genes were dif-
ferentially expressed due to stimulation with LPS
(ArrayExpress accession number E-TABM-483). Six of
these genes were also differentially expressed in our in
vivo study. For all results see additional file 4, supple-
mentary table 3.
Discussion
We applied a stepped approach in our study to provide
evidence that endotoxin exposure in vivo results in a
proatherogenic phenotype in circulating monocytes.
First, we proved that the LPS infusion model we applied
results in both clinical symptoms and increased IL-6, a
marker for inflammation associated with TLR4 signaling
(17), with IL-6 levels peaking at three hours post LPS
infusion. Second, circulating monocytes were profiled on
cDNA arrays pre and post LPS infusion. We generated a
list of 39 genes differentially expressed at one or four
hours post LPS infusion. A lack of overlap between
genes at both time points was observed, with only AKIP
being differentially expressed at both time points. This
observation is likely due to the sequential activation of
pathways after the LPS stimulus. In addition, this might
reflect different populations of monocytes contributing
to the transcriptome, since only 45% of monocytes
Table 2 Genes differentially expressed four hours after LPS infusion
Ensembl ID HUGO geneID Full name foldchange p-value
ENSG00000168383 HLA-DPB1 HLA class II histocompatibility antigen, DP(W4) beta chain precursor 0,44 4,2E-05
ENSG00000152518 ZFP36L2 Butyrate response factor 2 0,47 6,7E-05
ENSG00000158050 DUSP2 Dual specificity phosphatase 2 0,47 9,3E-04
ENSG00000148218 ALAD Delta-aminolevulinic acid dehydratase 2,04 8,2E-04
ENSG00000152684 PELO Pelota homolog 2,08 6,0 E-04
ENSG00000163220 S100A9 Calgranulin B 2,09 3,8 E-03
ENSG00000088986 DNCL1 Dynein light chain 1, cytoplasmic 2,15 8,2 E-04
ENSG00000134802 SLC43A3 Solute carrier family 43, member 3 2,17 3,1 E-03
ENSG00000163754 GYG Glycogenin-1 2,21 1,1 E-03
ENSG00000084733 RAB10 Ras-related protein Rab-10 2,23 9,0 E-04
ENSG00000137312 FLOT1 Flotillin-1 2,23 2,6 E-03
ENSG00000023330 ALAS1 5-aminolevulinate synthase, nonspecific, mitochondrial precursor 2,24 1,6 E-03
ENSG00000015475 BID BH3 interacting domain death agonist 2,27 2,6 E-03
ENSG00000123405 NFE2 Transcription factor NF-E2 45 kDa subunit 2,27 2,9 E-03
ENSG00000096238 CLIC1 Chloride intracellular channel protein 1 2,29 4,8 E-04
ENSG00000168439 STIP1 Stress-induced-phosphoprotein 1 2,29 3,1 E-03
ENSG00000101310 SEC23B Protein transport protein Sec23B 2,32 6,0 E-04
ENSG00000106211 HSPB1 Heat-shock protein beta-1 2,33 2,1 E-03
ENSG00000102265 TIMP1 Metalloproteinase inhibitor 1 precursor 2,33 3,1 E-03
ENSG00000170458 CD14 Monocyte differentiation antigen CD14 precursor 2,40 4,8 E-04
ENSG00000155926 SLA SRC-like-adapter 2,41 1,9 E-04
ENSG00000109971 HSPA8 Heat shock cognate 70 kDa protein 2,45 4,6 E-04
ENSG00000038427 VCAN Versican core protein precursor 2,45 8,5 E-06
ENSG00000106803 SC61B Protein transport protein Sec61 beta subunit 2,46 8,9 E-05
ENSG00000137462 TLR2 Toll-like receptor 2 precursor 2,77 2,5 E-04
ENSG00000156127 BATF ATF-like basic leucine zipper transcriptional factor B-ATF 3,13 2,3 E-04
ENSG00000171860 C3aR1 C3a anaphylatoxin chemotactic receptor 4,65 1,0 E-03
ENSG00000175756 AKIP Aurora kinase A-interacting protein 5,68 8,7 E-04
No genes were differentially expressed in the controls at T = 0 vs. T = 4.
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remain in circulation one hour after LPS stimulation. Of
these genes, 7 of 8 randomly selected candidates were
confirmed by RT-PCR. Finally, comparisons with our in
vitro data identified 6 overlapping genes (BATF, BID,
C3aR1, IL1RN, SEC61B and SLC43A3). Since C3aR1 has
been previously associated with inflammation and ather-
osclerosis this might be one of the interesting candidates
in our experiments to link both disorders. We will focus
our discussion on the genes which were differentially
expressed in both our in vivo and in vitro experiments.
The C3aR1 gene is located on chromosome 12. The
gene product is a highly ligand-specific membrane
receptor belonging to the family of the seven transmem-
brane domain G-protein-coupled receptors. C3aR1 is
expressed in monocytes, macrophages and endothelial
cells. Binding of C3 to C3aR1 induces a wide rang of
inflammatory and immune effects [11]. There are multi-
ple lines of evidence for the role of C3aR1 in
atherosclerosis.
At gene expression level, in samples of patients with
advanced peripheral artery disease (PAD) the gene was
expressed at a five times higher level in advanced com-
pared to intermediate atherosclerotic lesions [12]. At
protein level, advanced human coronary atherosclerosis
plaques express C3aR1 in contrast to normal coronary
intima [13]. In addition, signaling via C3aR1 promotes
plaque instability and can thus result in clinical sequelae
of acute coronary syndromes [13].
The direct causal role of C3aR1 is provided by the fact
that pertubaration of this gene in knock out mice mod-
els result in significant decrease in atherosclerotic lesion
size [14].
Putting the evidence together, we speculate the follow-
ing sequence of events. We realize that several pathways
will co-exist and this is merely one of them. Low grade
inflammation due to endotoxinemia results in the higher
expression of C3aR1 in vivo. Increased C3aR1 expres-
sion in turn results in a proatherogenic monocyte phe-
notype. Firstly, this results in increased atherosclerotic
lesion size. Secondly, it results in increased plaque
instability. Ultimately all these effect might result in
more clinical CVD events.
The up regulation of IL1RN and BATF, in contrast,
does not support our hypothesis of the circulating
monocyte with a proatherogenic phenotype.
IL1RN is a cytokine gene located on chromosome 2. It
is a negative regulator of IL-1 signalling and plays a role
as an anti-inflammatory cytokine in acute and chronic-
inflammation of the vascular wall. It is expressed by
macrophages, endothelial cells and smooth muscle cells.
Endogenous IL-Ra suppresses atherosclerosis in humans.
Decreased expression and not increased expression has
been associated with atherosclerotic plaques in mice
[15]. The increased expression of IL1RN might be an
internal protective mechanism to downlplay the effects
of systemic inflammation due to the LPS stimulus.
BATF is a nuclear basic leucine zipper protein and a
member of the AP-1 family of transcription factors
located on chromosome 14. It directly regulates key
components of the formation and function of follicular
helper T cells and antibody class switching in B cells
[16]. In B-cells the expression of BATF is also induced
by LPS and IL-6 [16]. Expression of BATF in rat fibro-
blast suppressed the production of Metalloproteinase
(MMP)-2 and MMP-9. MMPs are key players in athero-
thrombosis due to their extracellular matrix remodelling
properties and their functional effects on cells involved
in atherogenesis and atherosclerotic complications [17].
The role of BID, SEC61B, SLC43A3 in atherosclerosis
is not yet established.
BID is located on chromosome 22q and is a critical
mediator of inflammation and innate immunity [18].
Mechanistically, BID interacts with NOD1, NOD2 and
the IB kinase (IKK) complex, impacting NF-B and
extracellular signal-regulated kinase (ERK) signalling
[18]. Targeting BID by small molecules has been pro-
posed as a way to treat immune-mediated inflammatory
disease including inflammatory bowel disease.
SEC61B is located on chromosome 9q22. In the Endo-
plasmatic Recticulum (ER) membrane, the heterotri-
meric Sec61 complex comprises three transmembrane
subunits (Sec61a, Sec61b, and Sec61g in mammals) and
forms protein-conducting channels, collectively termed a
translocon. Sec61a is known to be stabilized by Sec61g
and mainly responsible for the translocation activity in
the ER. In contrast to the other two subunits, Sec61b
can be stable on its own, and its function is not as well
defined. It is known that Sec61b in the inner nucleus
membrane (INM) is required for the release of epider-
mal growth factor from the INM to the nucleus [19].
SLC43A3 is located on chromosome 11 and is known
to be highly expressed in macrophages. It is thought to
function as a transporter of metabolites and nutrients
that are necessary during developmental events, such as
organogenesis [20]. It is part of the specific expression
pattern of the micro vascular endothelium and has been
proposed as putative drug target to pathological angio-
genesis [21].
Our study has several limitations. The experiments
were conducted in a small number of individuals. How-
ever the results are supported by the fact that the
selected candidate genes were validated by RT-PCR. In
addition, several genes have been previously described
in the literature as being differentially expressed in
response to endotoxin exposure [22,23]. In our experi-
ment we determined the effect of LPS on gene expres-
sion in circulating monocytes. However, a substantial
part of the monocytes migrated into the vessel wall,
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reflected by a fall in monocyte count in the peripheral
blood after LPS infusion. Therefore it begs questioning
how representative these circulating monocytes are for
the entire population of these cells [24]. In this respect,
the overlap in genes differentially expressed in our in
vivo study compared to previous in vitro LPS challenges,
lends further support to the validity of the identified
candidate genes in circulating monocytes. However, the
low level of homology between in vivo and in vitro tran-
scriptomes makes us question the value of studying
expression profiles of circulating cells as (prognostic)
markers for disease states. The poor overlap between in
vivo and in vitro experiments could be due to either the
intrinsic differences between the two systems or due to
the small sample sizes in both studies.
Another limitation is that the procedure of monocyte
isolation is time consuming and might thus effect tran-
scription and stability. To minimize these potential
effects, for all in vivo and in vitro experiments the same
optimized protocol was used by the same analyst.
Furthermore genes differentially expressed due to hand-
ling would have showed up in the placebo experiments.
No genes were differentially expressed in these
experiments.
Finally, in comparison to in vitro experiments only a
small number of genes were differentially expressed.
This is in part due to the stringent quality control cri-
teria we applied during the analysis, the limited coverage
of the microarrays and the fact that TLR4 signaling is
modulated in vivo by a number of specific pathways.
Conclusion
Endotoxin exposure in in vivo to healthy individuals
identified several candidate genes through which sys-
temic inflammation can result in accelerated athero-
sclerosis. Out of these candidates, C3aR1, might be a
promising target, solely based on the existing literature.
Our results in combination with previous reports sup-
port the possible role of anaphylatoxins and the comple-
ment system as potential target for treatment of acute
sequels of atherosclerosis through plaque stabilization.
Additional material
Additional file 1: Supplementary Methods. Full methods of the in vitro
experiments.
Additional file 2: LPS Supplementary Table 1. RNA yield and quality
data for all samples and those included in the study.
Additional file 3: LPS Supplementary Table 2. cDNA quantity, quality,
labeling and amplification data for all samples and those included in the
study.
Additional file 4: Supplementary Table 3 Ctrl vs LPS in vitro. Full
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